72 related articles for article (PubMed ID: 20358162)
1. Apolipoproteins: emerging biomarkers for CAD.
Goswami B
Singapore Med J; 2010 Feb; 51(2):179. PubMed ID: 20358162
[No Abstract] [Full Text] [Related]
2. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease.
Ogasawara K; Mashiba S; Hashimoto H; Kojima S; Matsuno S; Takeya M; Uchida K; Yajima J
Clin Chim Acta; 2008 Nov; 397(1-2):42-7. PubMed ID: 18691566
[TBL] [Abstract][Full Text] [Related]
4. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
5. [Low concentrations of high-density lipoproteins (HDL) in plasma and coronary artery disease].
Pérez-Méndez O; Luc G; Posadas-Romero C
Arch Inst Cardiol Mex; 2000; 70(3):312-21. PubMed ID: 10959461
[No Abstract] [Full Text] [Related]
6. Optimized automated apolipoprotein A-I assays as markers for coronary artery disease.
Levinson SS; Hobbs GA
Arch Pathol Lab Med; 1997 Jul; 121(7):678-84. PubMed ID: 9240901
[TBL] [Abstract][Full Text] [Related]
7. Which lipid measures are prognostic indicators of cardiovascular disease in women?
Oettgen P
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):190-1. PubMed ID: 16932280
[No Abstract] [Full Text] [Related]
8. Lipid Pentad Index: A novel bioindex for evaluation of lipid risk factors for atherosclerosis in young adolescents and children of premature coronary artery disease patients in India.
Das B; Daga MK; Gupta SK
Clin Biochem; 2007 Jan; 40(1-2):18-24. PubMed ID: 17052698
[TBL] [Abstract][Full Text] [Related]
9. [Should apolipoproteins be the first choice in routine health care?].
Järhult B; Lindström K
Lakartidningen; 2007 Oct 17-23; 104(42):3124. PubMed ID: 17985715
[No Abstract] [Full Text] [Related]
10. [Evaluation of the coronary risk: is it enough to asses ApoB/ApoA1 ratio only or is plasma lipoprotein concentration still necessary?].
Cybulska B
Kardiol Pol; 2005 Feb; 62(2):153-6. PubMed ID: 15815801
[No Abstract] [Full Text] [Related]
11. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
Zambon A; Brown BG; Deeb SS; Brunzell JD
J Intern Med; 2006 May; 259(5):473-80. PubMed ID: 16629853
[TBL] [Abstract][Full Text] [Related]
12. The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease.
Khadem-Ansari MH; Rasmi Y; Rahimi-Pour A; Jafarzadeh M
Singapore Med J; 2009 Jun; 50(6):610-3. PubMed ID: 19551315
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of apolipoprotein M as a biomarker of coronary artery disease.
Su W; Jiao G; Yang C; Ye Y
Clin Biochem; 2009 Mar; 42(4-5):365-70. PubMed ID: 19100249
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of replacing conventional plasma lipids with apolipoprotein measurement.
Lippi G; Targher G; Guidi GC
Acta Cardiol; 2009 Jun; 64(3):413-4; author reply 414. PubMed ID: 19593956
[No Abstract] [Full Text] [Related]
15. Plasma protein lipofuscin-like fluorophores in men with coronary artery disease treated with statins.
Sutherland WH; Williams MJ; de Jong SA
Arch Med Res; 2007 Oct; 38(7):757-63. PubMed ID: 17845895
[TBL] [Abstract][Full Text] [Related]
16. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.
Marcovina S; Packard CJ
J Intern Med; 2006 May; 259(5):437-46. PubMed ID: 16629849
[TBL] [Abstract][Full Text] [Related]
17. Apolipoproteins: promising biomarkers for cardiovascular risk prediction.
Romero-Corral A; Somers VK; Lopez-Jimenez F
J Intern Med; 2008 Jul; 264(1):1-3. PubMed ID: 18554334
[No Abstract] [Full Text] [Related]
18. Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease.
Schlitt A; Blankenberg S; Bickel C; Meyer J; Hafner G; Jiang XC; Rupprecht HJ
Int J Cardiol; 2005 Jul; 102(3):477-85. PubMed ID: 16004894
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
20. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy.
Walldius G; Jungner I
Eur Heart J; 2005 Feb; 26(3):210-2. PubMed ID: 15618031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
